Zacks: Analysts Expect Amyris Inc (AMRS) to Post -$0.30 EPS

Share on StockTwits

Wall Street analysts expect Amyris Inc (NASDAQ:AMRS) to announce earnings per share (EPS) of ($0.30) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Amyris’ earnings. Amyris reported earnings per share of ($0.52) during the same quarter last year, which would suggest a positive year-over-year growth rate of 42.3%. The firm is expected to report its next quarterly earnings results on Monday, May 13th.

According to Zacks, analysts expect that Amyris will report full year earnings of ($0.19) per share for the current financial year. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Amyris.

Amyris (NASDAQ:AMRS) last issued its earnings results on Monday, March 18th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.44 by ($1.51). The company had revenue of $19.36 million for the quarter, compared to the consensus estimate of $98.52 million. During the same quarter in the prior year, the company earned $0.61 EPS. The company’s revenue was down 76.0% compared to the same quarter last year.

AMRS has been the topic of several research reports. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. BidaskClub upgraded shares of Amyris from a “sell” rating to a “hold” rating in a report on Monday, January 7th. Finally, HC Wainwright set a $11.00 target price on shares of Amyris and gave the stock a “buy” rating in a report on Tuesday, February 5th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Amyris currently has an average rating of “Buy” and an average target price of $8.83.

AMRS stock traded up $0.36 on Thursday, hitting $4.41. The company had a trading volume of 40,890 shares, compared to its average volume of 4,582,411. Amyris has a 12-month low of $1.87 and a 12-month high of $9.28. The stock has a market capitalization of $309.95 million, a P/E ratio of -1.74 and a beta of 0.84.

In other Amyris news, Director L John Doerr purchased 6,732,369 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were acquired at an average price of $2.87 per share, for a total transaction of $19,321,899.03. Following the purchase, the director now directly owns 5,532 shares of the company’s stock, valued at approximately $15,876.84. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Frank Kung purchased 913,529 shares of the company’s stock in a transaction dated Monday, April 29th. The shares were acquired at an average price of $4.76 per share, for a total transaction of $4,348,398.04. Following the purchase, the director now directly owns 3,599 shares in the company, valued at $17,131.24. The disclosure for this purchase can be found here. Insiders have bought a total of 10,478,338 shares of company stock worth $38,172,390 in the last quarter. Corporate insiders own 21.80% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Amyris by 50.2% during the 4th quarter. BlackRock Inc. now owns 3,419,786 shares of the biotechnology company’s stock worth $11,421,000 after acquiring an additional 1,142,354 shares during the last quarter. Deutsche Bank AG raised its position in shares of Amyris by 2,498.9% during the 4th quarter. Deutsche Bank AG now owns 1,626,582 shares of the biotechnology company’s stock valued at $5,431,000 after purchasing an additional 1,563,994 shares during the period. Northpointe Capital LLC raised its position in shares of Amyris by 37.9% during the 4th quarter. Northpointe Capital LLC now owns 633,015 shares of the biotechnology company’s stock valued at $2,114,000 after purchasing an additional 173,853 shares during the period. WS Management Lllp bought a new stake in shares of Amyris during the 4th quarter valued at $2,101,000. Finally, JPMorgan Chase & Co. raised its position in shares of Amyris by 96.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 446,909 shares of the biotechnology company’s stock valued at $3,548,000 after purchasing an additional 219,081 shares during the period. Institutional investors and hedge funds own 35.94% of the company’s stock.

About Amyris

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Featured Article: Municipal Bonds

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

IBM  Research Coverage Started at JPMorgan Chase & Co.
IBM Research Coverage Started at JPMorgan Chase & Co.
Air Products & Chemicals  Rating Lowered to Market Perform at Sanford C. Bernstein
Air Products & Chemicals Rating Lowered to Market Perform at Sanford C. Bernstein
Obsidian Energy  Rating Lowered to Hold at Zacks Investment Research
Obsidian Energy Rating Lowered to Hold at Zacks Investment Research
Keefe, Bruyette & Woods Upgrades Bank of New York Mellon  to Market Perform
Keefe, Bruyette & Woods Upgrades Bank of New York Mellon to Market Perform
SALZGITTER AG/ADR  Stock Rating Lowered by Zacks Investment Research
SALZGITTER AG/ADR Stock Rating Lowered by Zacks Investment Research
SOCO International  Lifted to Hold at Zacks Investment Research
SOCO International Lifted to Hold at Zacks Investment Research


 
© 2006-2019 Zolmax.